Press Release
Novato, CA, U.S., June 24, 2022 – Announcing our move to the Buck Institute for Research on Aging.
Cyclarity Therapeutics (https://cyclaritytx.com) has just completed the move of its research and operations to the state-of-the-art labs at the Buck Institute for Research on Aging. We presented the progress of our lead program to the President and Senior Officers of the Buck Institute earlier this year, and they kindly extended an offer of tenancy.
Our relationship with the Buck Institute offers not only access to a variety of important core facilities; we expect it offers a wonderful opportunity to expand our collaborations and relationships with many world leaders in cardiovascular disease, and the field of aging as a whole.
About Cyclarity
Cyclarity Therapeutics, Inc., is pursuing a mission to treat the underlying causes of age-related disease. The company develops simple and direct interventions targeting oxidized cholesterol using rationally designed molecules, to provide the first true disease-modifying treatments for common age-related conditions such as atherosclerosis, heart attack and stroke. Its products are based on novel derivatives of a well-known, safe compound and a new way of looking at cardiovascular disease. For more information, please visit www.cyclaritytx.com or send an email to press@cyclaritytx.com
Forward Looking Statements
The information and statements contained herein contain forward-looking statements, which are subject to risks and uncertainties that could cause actual results to differ materially from such forward-looking statements and should not be considered as an indication or guarantee of future performance. Forward-looking statements involve known and unknown risks and uncertainties which could cause the Company’s prospects or actual results to differ materially from those in the forward-looking statements. The Company does not undertake any obligation to update the information or forward-looking statements contained herein whether as a result of new information or future events or otherwise.
Contact:
Mike Kope
CEO of Corporate Affairs
Cyclarity Therapeutics, Inc.
press@cyclaritytx.com
